MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer's drug Aduhelm than it normally would for a Part B drug.

For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm

MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer’s drug Aduhelm than it normally would for a Part B drug.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report